Blog

David Sebag: The first patient was randomised in the ARTEMIS organ preservation phase II rectal cancer trial at Leeds Teaching Hospitals

Photo taken from David Sebag-Montefiore/LinkedIn

Apr 1, 2024, 09:54

David Sebag: The first patient was randomised in the ARTEMIS organ preservation phase II rectal cancer trial at Leeds Teaching Hospitals

David Sebag, Professor of Clinical Oncology and Health Research at University of Leeds, shared on X:

“Fantastic news! Following last week’s brilliant hybrid workshop at University of Leeds, the first patient was randomised in the ARTEMIS organ preservation phase II rectal cancer trial at Leeds Teaching Hospitals today!
Huge congrats to the team!

ARTEMIS will test the benefits of adding Adlai Nortye AN0025 to short course and long course CRT. It is a selective inhibitor of EP4, one of four PGE2 receptors, a strong pre-clinical rationale and a high CR rate in early phase.
doi: 10.1016/j.radonc.2023.109669

You can read more about this study here.”

Source: David Sebag/X

Adlai Nortye ARTEMIS cancer CRT David Sebag Leeds Teaching Hospitals OncoDaily Oncology PGE2 receptors rectal cancer selective inhibitor of EP4 Trial University of Leeds

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage